地诺孕素/戊酸雌二醇(Dienogest/Estradiol Valerate) - 药物靶点：ER x PR_在研适应症：月经过多，避孕，原发性痛经_专利_临床

概要

基本信息

药物类型

小分子化药

别名

ESTRADIOL VALERATE/ESTRADIOL VALERATE/DIENOGEST、Natazia

靶点

ER x PR

作用机制

ERs激动剂(雌激素受体家族激动剂)、PR激动剂(孕激素受体激动剂)

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

Bayer HealthCare Pharmaceuticals, Inc.

University of Siena

非在研机构

Bayer AG

拜耳医药保健有限公司Schering GmbH & Co. Produktions KG

+ [1]

最高研发阶段批准上市

首次获批日期

美国 (2010-05-06),

避孕

最高研发阶段(中国)无进展

特殊审评-

登录后查看时间轴

结构

分子式C20H25NO2

InChIKeyAZFLJNIPTRTECV-FUMNGEBKSA-N

CAS号65928-58-7

查看全部结构式(2)

关联

26

项与地诺孕素/戊酸雌二醇相关的临床试验

TCTR20240908003 / Not yet recruiting临床4期IIT

A comparison of menstrual volume and other benefits between Estradiol valerate/dienogest and Ethinyl estradiol/desogestrel: A randomized controlled trial

开始日期2024-09-01

申办/合作机构

Srinakharinwirot University

NCT06396208 / RecruitingN/AIIT

"Quick-starting" of a Quadriphasic Contraceptive Pills, 1 - 3 mg Estradiol Valerate/ 2 - 3 mg Dienogest VS 20 mcg Ethinylestradiol/75 mcg Gestodene Focusing on Ovulation Inhibition: A Single-blind, Randomized Controlled, Non-inferiority Trial

The goal of this clinical trial is to learn if Estetrol/Drospirenone inhibit ovulation in quick-starting method. It will also learn about the safety of Estetrol/Drospirenone. The main questions it aims to answer are:
Does Estradiol valerate/Dienogest inhibit ovulation inferior to Ethinyl estradiol/Gestodene when starting on Day 7-9 of menstrual cycle? What are the impacts of Estradiol valerate/Dienogest on ovarian activities when starting on Day 7-9 of menstrual cycle? How does the cervical mucus change when starting Estradiol valerate/Dienogest on Day 7-9 of menstrual cycle? What are the adverse effects when starting Estradiol valerate/Dienogest on Day 7-9 of menstrual cycle? Researchers will compare Estradiol valerate/Dienogest to Ethinyl estradiol/Gestodene to see if Estradiol valerate/Dienogest inhibit ovulation in quick-starting method.

开始日期2024-05-01

申办/合作机构

University of Chulalongkorn

NCT05332106 / Completed临床1期

Bioavailability of a Formulation of Estradiol Valerate and Dienogest 2 mg/2 mg Coated Tablets With Regards to the Marketed Reference Product

This study will investigate the bioavailability in fasting healthy, adult, human post-menopausal female subjects of 1 tablet formulation containing Estradiol Valerate and Dienogest 2 mg/ 2mg.
The study will be performed at a single site with 10 subjects. Participants will take 1 tablet of the test product and reference product in 2 periods and 2 sequences (either test after reference or reference after test). There will be a washout of at least 7 days between each study period.

开始日期2022-03-12

申办/合作机构

Laboratorios Andrómaco SA

100 项与地诺孕素/戊酸雌二醇相关的临床结果

登录后查看更多信息

100 项与地诺孕素/戊酸雌二醇相关的转化医学

登录后查看更多信息

100 项与地诺孕素/戊酸雌二醇相关的专利（医药）

登录后查看更多信息

13

项与地诺孕素/戊酸雌二醇相关的文献（医药）

2024-06-01·Journal of Assisted Reproduction and Genetics

Impact of dydrogesterone use in cycles with low progesterone levels on the day of frozen embryo transfer

Article

作者: Ferreira, Pedro ; Natário, Isabel ; Santos-Ribeiro, Samuel ; Metello, Jose ; Tomás, Claudia

PURPOSEThis study aims to evaluate whether the clinical outcomes of cycles with frozen embryo transfer (FET) in hormonal replacement treatment supplemented with dydrogesterone (DYD) following detection of low circulating levels of progesterone (P4) were comparable to the results of cycles with otherwise normal serum P4 values.METHODSExtended analyses of a retrospective cohort that included FET cycles performed between July 2019 and March 2022 after a cycle of artificial endometrial preparation using valerate-estradiol and micronized vaginal P4 (400 mg twice daily). Whenever the serum P4 value was considered low on the morning of the planned transfer, 10 mg of DYD three times a day was added as a supplement. Only single-embryo transfers of a blastocyst were considered. The primary endpoint was live birth rate.RESULTSFive-hundred thirty-five FET cycles were analyzed, of which 136 (25.4%) underwent treatment with DYD. There were 337 pregnancies (63%), 207 live births (38.6%), and 130 miscarriages (38.5%). The P4 values could be modeled by a gamma distribution, with a mean of 14.5 ng/ml and a standard deviation of 1.95 ng/ml. The variables female age on the day of FET, ethnicity, and weight were associated with a variation in the serum P4 values. There were no differences in the results between cycles with or without the indication for DYD supplementation.CONCLUSIONSLive birth rate did not vary significantly in females with low and normal serum P4 levels on the day of FET when DYD was used as rescue therapy.

2018-03-01·Journal of Assisted Reproduction and Genetics3区 · 医学

Estrogen treatment in infertile women with premature ovarian insufficiency in transitional phase: a retrospective analysis

3区 · 医学

Article

作者: Sergiampietri, Claudia ; Simi, Giovanna ; Basile, Stefano ; Giannarelli, Diana ; Artini, Paolo Giovanni ; Obino, Maria Elena Rosa ; Cela, Vito ; Pinelli, Sara

PURPOSEDuring the transitional phase of premature ovarian insufficiency (POI), sporadic resumption of ovulation is possible because of fluctuation of hormonal levels but the chance of spontaneous pregnancy is low, and the main perspective of childbearing in these women is egg donation or adoption. The purpose of the study was to verify whether treatment with estrogens in POI patients in transitional phase could reduce FSH levels and to evaluate if this pre-treatment could improve reproductive outcomes of in vitro fertilization (IVF).METHODSStudy patients (26) were administered with valerate estradiol 2 mg daily adding dihydrogesterone 10 mg daily during luteal phase for 3 months before IVF. Control group (26 patients) did not receive any pre-treatment. Ovarian stimulation was conducted in both groups with the same short GnRH-antagonist protocol. Clinical and laboratory data of patients were retrospectively analyzed.RESULTSIn the study group, 4/26 POI patients became spontaneously pregnant during pre-treatment. In the remaining patients, the mean level of FSH after the pre-treatment was significantly reduced compared with baseline. Levels of circulating estradiol on the day of hCG administration were significantly higher in the study group. The total number of MII oocytes retrieved and fertilized oocytes was significantly higher in the study group, as well as the number of embryos transferred for pickup and clinical pregnancy rate.CONCLUSIONSTreatment with estrogens in infertile POI patients in transitional phase reduces circulating FSH levels, hence causing potential spontaneous conception. Moreover, in these patients, estrogen pre-treatment seems to improve IVF outcomes in a GnRH-antagonist short protocol compared to no pre-treatment.

2014-11-01·Gynecological Endocrinology4区 · 医学

Effects of estroprogestins containing natural estrogen on vaginal flora

4区 · 医学

Article

作者: Francesco De Seta ; Stefano Lello ; Stefano Restaino ; Ester Conversano ; Rossella De Leo ; Gianpaolo Maso ; Rubina Banco ; Maddalena Tonon ; Giulia Barbati

Estroprogestins with "natural oestrogen" has represented a new option in terms of combined hormonal contraception. So, the aim of this study is to investigate how estroprogestins with natural estrogen may modify the vaginal niche. In literature, very few studies focused on the interaction between hormonal contraception and vaginal milieu. This is a prospective comparative study. We enrolled 60 women from January 2013 to September 2013, 30 of them were administered estradiol valerate dienogest (E2V+DNG - Klaira®) in a quadriphasic regimen, while the other 30 women were administered 17-β estradiol with nomestrol acetate (EV+NOMAC - Zoely®) in a monophasic regimen. After a baseline study of vaginal milieu at recruitment of patients (Gram stain with Nugent score, vaginal pH, vaginal wet mount for the quantification of leukocytes, Lactobacilli and/or presence of Candida), we performed the same follow-up after six months of estroprogestin therapy. Our results showed that the women treated with E2V+DNG had a trend of an improvement of vaginal health in terms of increase of lactobacillar flora and reduction of vaginal pH in place of women treated with EV+NOMAC that showed a reduction of cervical mucus. Finally, our data about the effects on vaginal flora exerted by two estroprogestin pills (EPs) containing a natural estrogen suggest slight, but interesting differences in terms of vaginal ecology. These differences could be related to the type of estrogen, type of progestin, regimen of administration and, after all, to the net balance between estrogenic and progestin component of the EPs.

100 项与地诺孕素/戊酸雌二醇相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	G03AB08	-

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
月经过多	美国	Bayer HealthCare Pharmaceuticals, Inc.	2012-03-14
避孕	美国	Bayer HealthCare Pharmaceuticals, Inc.	2010-05-06

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
头痛	药物发现	芬兰	Bayer AG	2008-12-01
头痛	药物发现	西班牙	Bayer AG	2008-12-01
头痛	药物发现	瑞士	Bayer AG	2008-12-01
头痛	药物发现	法国	Bayer AG	2008-12-01
头痛	药物发现	墨西哥	Bayer AG	2008-12-01
头痛	药物发现	澳大利亚	Bayer AG	2008-12-01
头痛	药物发现	德国	Bayer AG	2008-12-01
避孕	药物发现	捷克	Bayer AG	2005-03-01
避孕	药物发现	德国	Bayer AG	2005-03-01
避孕	药物发现	法国	Bayer AG	2005-03-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02352090 (SYLVI, CTgov)	临床4期	炎症 \| 避孕	59	Ethinyl estradiol / dienogest (Synthetic Estrogen + Progestin)	鏇鏇積鏇製選鹹觸遞齋(鑰製窪壓鑰鑰襯繭範觸) = 繭壓鏇鏇憲構蓋齋壓顧網鹹選廠鬱積顧淵壓醖 (夢鑰範壓廠願糧遞艱觸, 壓壓鑰觸範網廠鹽積顧 ~ 網齋鹹獵築獵蓋範夢蓋) 更多	-	2021-06-29
				Estradiol valerate / dienogest (Natural Estrogen + Progestin)	鏇鏇積鏇製選鹹觸遞齋(鑰製窪壓鑰鑰襯繭範觸) = 衊網壓製窪積獵淵壓觸網鹹選廠鬱積顧淵壓醖 (夢鑰範壓廠願糧遞艱觸, 遞願願壓鏇醖鹽網廠壓 ~ 鬱醖網獵獵網鏇憲範製) 更多
NCT01638910 (Pubmed \| Int J Womens Health)	临床3期	-	954	Estradiol valerate/dienogest	鹹顧築鹽膚鏇鹹觸齋淵(鏇齋繭築製艱窪壓憲顧) = 遞夢簾窪積鏇顧範願鹹網鬱鑰壓築夢願艱衊構 (簾顧窪遞膚觸製構鹹選 )	-	2018-01-01
NCT00754065 (CTgov)	临床3期	避孕	409	Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027) (Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027))	簾糧夢淵顧壓願獵鹽鹹(蓋蓋襯構鬱製壓膚鬱願) = 夢餘蓋夢蓋顧選築憲壓繭鑰夢願觸夢選餘獵積 (獵遞醖壓壓淵壓獵獵鑰, 構廠衊網鬱鹹繭鹹獵鹹 ~ 鹹淵觸鬱範簾鏇窪繭鏇) 更多	-	2012-08-28
				Ortho Tri Cyclen Lo (Ortho Tri-Cyclen Lo)	簾糧夢淵顧壓願獵鹽鹹(蓋蓋襯構鬱製壓膚鬱願) = 鏇構餘製衊醖齋顧選蓋繭鑰夢願觸夢選餘獵積 (獵遞醖壓壓淵壓獵獵鑰, 膚淵憲遞獵齋艱構襯蓋 ~ 襯齋鬱壓壓獵選築衊齋) 更多
NCT00764881 (CTgov)	临床3期	女性性功能障碍 \| 避孕	217	EV/DNG (Qlaira, BAY86-5027, SH T00658ID) (EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID))	鬱醖鏇餘構齋觸襯廠鹽(鏇獵選構鹽鹽壓獵網鏇) = 範選觸蓋觸製餘觸淵壓艱鏇構窪範遞糧壓觸齋 (製積齋衊製壓構廠願鹹, 齋網選鬱鏇選製窪製製 ~ 醖鹽廠鬱淵壓憲窪鑰蓋) 更多	-	2012-04-03
				Placebo+Microgynon (EE/LNG (Microgynon) + Placebo)	鬱醖鏇餘構齋觸襯廠鹽(鏇獵選構鹽鹽壓獵網鏇) = 構網餘獵繭製顧選鏇願艱鏇構窪範遞糧壓觸齋 (製積齋衊製壓構廠願鹹, 鹽觸鹽築鑰鹽鹽襯鑰鑰 ~ 壓繭構襯遞齋膚蓋糧顧) 更多
NCT00909857 (CTgov)	临床3期	原发性痛经	507	Placebo Match to SH T00658ID+Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027) (Estradiol Valerate, Dienogest (Natazia, Qlaira, BAY86-5027))	遞廠艱簾艱壓壓鏇憲齋(網鬱鏇衊糧艱鏇製淵糧) = 獵簾齋構築簾夢築顧築鏇顧夢築蓋憲選鑰衊膚 (廠壓壓鹹願網願壓築壓, 窪繭構獵遞艱壓壓鑰衊 ~ 網範襯鑰壓蓋窪製襯製) 更多	-	2012-02-27
				Placebo Match to SH D593B+Ethinyl estradiol, Levonorgestrel (Miranova) (Ethinyl Estradiol, Levonorgestrel (Miranova))	遞廠艱簾艱壓壓鏇憲齋(網鬱鏇衊糧艱鏇製淵糧) = 淵糧淵衊壓製餘顧鹹襯鏇顧夢築蓋憲選鑰衊膚 (廠壓壓鹹願網願壓築壓, 夢餘範選獵壓窪憲廠齋 ~ 醖顧選淵範衊淵網鬱鑰) 更多